Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2222-2229

  Hu, Chang Chen ^a,b   Ji, Hong Ming ^b   Chen, Sheng Li ^b,c   Zhang, Han Wei ^b   Wang, Bin Quan ^d   Zhou, Li Yuan ^d   Zhang, Zi Ping ^b   Sun, Xin Lin ^a   Chen, Zhen Zhou ^a   Cai, Ying Qian ^a   Qin, Ling Sha ^a   Lu, Li ^d   Jiang, Xiao Dan ^a   Xu, Ru Xiang ^a   Ke, Yi Quan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

antiangiogenic therapy; genetic vectors; immunotoxin; malignant glioma; PE38; VEGF165

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; IMMUNOTOXIN; UNCLASSIFIED DRUG; VASCULOTROPIN 165 PSEUDOMONAS EXOTOXIN 38; BACTERIAL TOXIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER MODEL; CELL STRAIN HEK293; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROVESSEL DENSITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SUPERNATANT; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; FEASIBILITY STUDY; GENE THERAPY; GENETICS; GLIOMA; HUMAN; METABOLISM; NUDE MOUSE; PSEUDOMONAS; TUMOR CELL LINE; VASCULARIZATION;

ADP RIBOSE TRANSFERASES; ANGIOGENESIS INHIBITORS; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; EXOTOXINS; FEASIBILITY STUDIES; GENE THERAPY; GLIOMA; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PLASMIDS; PSEUDOMONAS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956643638     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25217     Document Type: Article

References (39)

1. Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, et al. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2007; 17: 441 -6.
2. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401 -10.
3. Kerbel RS,. Tumor angiogenesis. N Engl J Med 2008; 358: 2039 -49.
4. Gille J,. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor-and growth factor receptor-targeted approaches. Exp Dermatol 2006; 15: 175 -86.
5. Pastan I, Chaudhary V, FitzGerald DJ,. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 1992; 61: 331 -54.
6. Wolf P, Elssser-Beile U,. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 2009; 299: 161 -76.
7. Ellis LM, Hicklin DJ,. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579 -91.
8. Hu CC, Ke YQ, Sun XL, Jiang XD, Xu RX, Lv J, Wang YS, Cai YQ, Qin LS, Zou YX,. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett 2009; 31: 181 -9.
9. Baker D, Hankey DJ,. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther 2003; 10: 844 -53.
10. Sobol RE, Scanlon KJ,. Cancer gene therapy clinical trials. Cancer Gene Ther 1995; 2: 5 -6.
11. Scanlon KJ,. Cancer gene therapy: challenges and opportunities. Anticancer Res 2004; 24: 501 -4.
12. Risau W,. Mechanisms of angiogenesis. Nature 1997; 386: 671 -4.
13. Zhou ZJ, Liu YL, Wu PS, Li XW, Zha DG, Zhou Y,. Cloning of expression vector for VEGF121 and VEGF165 genes encoding human vascular endothelial growth factor. Di Yi Jun Yi Da Xue Xue Bao 2002; 22: 111 -13.
14. Kirchner LM, Schmidt SP, Gruber BS,. Quantitation of angiogenesis in the chick chorioallantoic membrane model using fractal analysis. Microvasc Res 1996; 51: 2 -14.
15. Siamblis D, Karnabatidis D, Hatjikondi O, Kalogeropoulou C, Kardamakis D, Dimopoulos J,. A novel radiological approach for the experimental study of angiogenesis: angiography of the chick embryo and its chorioallantoic membrane. Eur J Radiol 1996; 21: 220 -4.
16. Storgard C, Mikolon D, Stupack DG,. Angiogenesis assays in the chick CAM. Methods Mol Biol 2005; 294: 123 -36.
17. Osborne CK, Hobbs K, Clark GM,. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584 -90.
18. Rak J, Filmus J, Kerbel RS,. Reciprocal paracrine interactions between tumour cells and endothelial cells: the angiogenesis progression hypothesis. Eur J Cancer 1996; 32A: 2438 -50.
19. Sanai N, Alvarez-Buylla A, Berger MS,. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811 -22.
20. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182 -6.
21. Bolontrade MF, Zhou RR, Kleinerman ES,. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002; 8: 3622 -7.
22. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127 -32.
23. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592 -603.
24. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS,. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999; 59: 183 -8.
25. Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA,. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg 2002; 6: 159 -66.
26. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I,. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999; 5: 2311 -5.
27. Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003; 63: 3173 -80.
28. Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, Cong Y, Yao C, Huang XF,. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997; 385: 78 -80.
29. Vallera DA, Jin N, Baldrica JM, Panoskaltsis-Mortari A, Chen SY, Blazar BR,. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 2000; 60: 976 -84.
30. Liu YY, Gordienko I, Mathias A, Ma S, Thompson J, Woo JH, Neville DM Jr,. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line. Protein Expr Purif 2000; 19: 304 -11.
31. Jia J, Li H, Tai S, Lv M, Liao M, Yang Z, Zhang B, Zhou B, Zhang G, Zhang L,. Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis. DNA Cell Biol 2008; 27: 279 -85.
32. Fabbrini MS, Carpani D, Soria MR, Ceriotti A,. Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J 2000; 2: 391 -8.
33. Hessler JL, Kreitman RJ,. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997; 36: 14577 -82.
34. Chiron MF, Fryling CM, FitzGerald DJ,. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994; 269: 18167 -76.
35. Kreitman RJ,. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8: E532 -51.
36. Takada T, Iida K, Awaji T, Itoh K, Takahashi R, Shibui A, Yoshida K, Sugano S, Tsujimoto G,. Selective production of transgenic mice using green fluorescent protein as a marker. Nat Biotechnol 1997; 15: 458 -61.
37. Levy JP, Muldoon RR, Zolotukhin S, Link CJ Jr,. Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells. Nat Biotechnol 1996; 14: 610 -14.
38. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, Sorrentino BP, Nienhuis AW,. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997; 90: 1777 -86.
39. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A,. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363 -9.